Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN D BECKES

Allopathic & Osteopathic Physicians Hospitalist

NPI
1639118912
CMS profile
836653
Location
NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$3,065.23

9 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,395.48 6
Food and Beverage $669.75 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $3,045.87 8
Novartis Pharmaceuticals Corporation $19.36 1

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN D BECKES

NPI 1639118912 · CMS profile ID 836653

Allopathic & Osteopathic Physicians / Hospitalist

NATIONAL CITY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639118912?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639118912?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JOHN D BECKES, NPI 1639118912, CMS profile ID 836653. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639118912?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JOHN D BECKES, NPI 1639118912, CMS profile ID 836653, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–9 of 9 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1639118912?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

9 matching records · $3,065.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 9 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–9 of 9.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $280.5210/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981275 CMS
ModernaTX, Inc. $394.9310/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981279 CMS
ModernaTX, Inc. $367.8010/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981283 CMS
ModernaTX, Inc. $200.7410/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981287 CMS
ModernaTX, Inc. $255.4609/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981259 CMS
ModernaTX, Inc. $647.0009/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981271 CMS
ModernaTX, Inc. $684.8009/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981263 CMS
ModernaTX, Inc. $214.6209/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981267 CMS
Novartis Pharmaceuticals Corporation $19.3608/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991440231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $124.99 1
PY2023 $3,065.23 9
PY2024 $570.95 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,605,177.75 703
PY2024 Recipient $1,613.98 3
PY2024 Principal investigator $3,238,637.82 219
PY2023 Recipient $1,016.73 1
PY2023 Principal investigator $5,966,992.99 5,656
PY2022 Recipient $456.00 1
PY2022 Principal investigator $3,684,980.58 3,955

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

222 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Braintree Laboratories, Inc. $10,563.05 12/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204954
Principal investigator 1 Braintree Laboratories, Inc. $76.00 12/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204956
Principal investigator 1 Merck Sharp & Dohme LLC $1,352.60 12/31/2024 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults No dispute reported 06/30/2026 1136436552
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/30/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191766
Principal investigator 1 Braintree Laboratories, Inc. $4,065.00 12/25/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204802
Principal investigator 1 Braintree Laboratories, Inc. $38,685.00 12/25/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204804
Principal investigator 1 ModernaTX, Inc. $5,000.00 12/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191762
Principal investigator 1 PFIZER INC. $559.38 12/24/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130967604
Principal investigator 1 Braintree Laboratories, Inc. $152.00 12/18/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204684
Principal investigator 1 ModernaTX, Inc. $32,926.50 12/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191770
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $16,961.49 12/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082449770
Principal investigator 1 Braintree Laboratories, Inc. $280.00 12/17/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204604
Principal investigator 1 Braintree Laboratories, Inc. $183.00 12/17/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204606
Principal investigator 1 Boehringer Ingelheim International GmbH $18,512.00 12/16/2024 Non-covered Recipient Entity
Acclaim Clinical Research
BI 456906 in NASH F2/F3 - pivotal trial No dispute reported 06/30/2026 1101068387
Principal investigator 1 Boehringer Ingelheim International GmbH $18,512.00 12/16/2024 Non-covered Recipient Entity
Acclaim Clinical Research
BI 456906 in NASH F4 - pivotal trial No dispute reported 06/30/2026 1101074537
Principal investigator 1 Braintree Laboratories, Inc. $179,535.00 12/13/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204594
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $960.00 12/11/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189158
Principal investigator 1 Braintree Laboratories, Inc. $25,800.66 12/10/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204538
Principal investigator 1 PFIZER INC. $13,899.90 12/10/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130967598
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $35,295.54 12/10/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082447850
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $15,234.20 12/04/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,515.30 12/03/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082446760
Principal investigator 1 Braintree Laboratories, Inc. $100.00 12/02/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204448
Principal investigator 1 Braintree Laboratories, Inc. $1,292.00 12/02/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204450
Principal investigator 1 ModernaTX, Inc. $3,500.00 12/02/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191628
Principal investigator 1 PFIZER INC. $12,306.36 11/26/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130985100
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,060.71 11/26/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082445872
Principal investigator 1 Janssen Research & Development, LLC $385.00 11/21/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980215
Principal investigator 1 Janssen Research & Development, LLC $543.80 11/21/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980237
Principal investigator 1 Janssen Research & Development, LLC $455.00 11/21/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980603
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $250.00 11/20/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189878
Principal investigator 1 ModernaTX, Inc. $9,724.48 11/20/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191612
Principal investigator 1 Janssen Research & Development, LLC $7,740.00 11/19/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980427
Principal investigator 1 Janssen Research & Development, LLC $3,200.00 11/15/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980289
Principal investigator 1 Janssen Research & Development, LLC $750.00 11/15/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980391
Principal investigator 1 Janssen Research & Development, LLC $18,700.00 11/15/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980611
Principal investigator 1 Braintree Laboratories, Inc. $500.00 11/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204222
Principal investigator 1 Braintree Laboratories, Inc. $99.00 11/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204224
Principal investigator 1 Braintree Laboratories, Inc. $1,330.00 11/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204226
Principal investigator 1 Braintree Laboratories, Inc. $16,260.00 11/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204228
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $715.40 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444164
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $343.00 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444176
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,500.00 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444216
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,000.00 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444340
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $18,750.00 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444350
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,971.28 11/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082444396
Principal investigator 1 PFIZER INC. $839.07 11/08/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130984578
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,775.00 11/07/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,022.00 11/07/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $151,713.10 11/05/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082443666
Principal investigator 1 Braintree Laboratories, Inc. $8,566.00 10/29/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203664
Principal investigator 1 Braintree Laboratories, Inc. $8,873.00 10/29/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203666
Principal investigator 1 Braintree Laboratories, Inc. $219,325.00 10/29/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203668
Principal investigator 1 Braintree Laboratories, Inc. $16,375.65 10/29/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203670
Principal investigator 1 ModernaTX, Inc. $3,006.17 10/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191754
Principal investigator 1 ModernaTX, Inc. $2,135.36 10/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191756
Principal investigator 1 ModernaTX, Inc. $5,190.26 10/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191758
Principal investigator 1 ModernaTX, Inc. $20,721.29 10/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191760
Principal investigator 1 Janssen Research & Development, LLC $335.00 10/16/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980561
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,360.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189608
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $24,695.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189610
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,020.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189612
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $400.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189614
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,228.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189616
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $544.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189618
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,798.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189620
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,192.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189622
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $680.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189624
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,754.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189626
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $9,720.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189628
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $4,964.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189630
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,020.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189632
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $35,920.00 10/16/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189682
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $128,248.10 10/09/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189606
Principal investigator 1 PFIZER INC. $3,453.00 10/08/2024 Non-covered Recipient Entity
Elligo Health Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1130994862
Principal investigator 1 Braintree Laboratories, Inc. $77,345.00 10/07/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203028
Principal investigator 1 PFIZER INC. $559.38 10/05/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1130994869
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,349.00 10/04/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189598
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $5,032.00 10/04/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189600
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,360.00 10/04/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189602
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $9,855.00 10/04/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211 No dispute reported 06/30/2026 1081189604
Principal investigator 1 Braintree Laboratories, Inc. $30,193.89 10/03/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202856
Principal investigator 1 Braintree Laboratories, Inc. $8,270.00 09/23/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202604
Principal investigator 1 Braintree Laboratories, Inc. $64,745.00 09/23/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202606
Principal investigator 1 ModernaTX, Inc. $9,231.30 09/20/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191604
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $43,207.00 09/18/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,100.00 09/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082438186
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.00 09/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082438190
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $392.00 09/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082438192
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,142.00 09/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082438208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,475.00 09/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082438214
Principal investigator 1 Braintree Laboratories, Inc. $16,830.15 09/13/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202156
Principal investigator 1 Janssen Research & Development, LLC $335.00 09/12/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980623
Principal investigator 1 PFIZER INC. $13,770.00 09/11/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131023936
Principal investigator 1 Novartis Pharmaceuticals Corporation $14,540.75 09/05/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease No dispute reported 06/30/2026 1089696949
Principal investigator 1 ModernaTX, Inc. $29,283.43 09/02/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191736
Principal investigator 1 PFIZER INC. $9,509.46 08/28/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131030386
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,296.00 08/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082434902
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,000.00 08/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082434912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $12,911.00 08/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082434920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,699.00 08/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-Blind Study of The Efficacy and Safety of Trevogrumab, With or Without Garetosmab, in Addition to Semaglutide in Patients With Obesity No dispute reported 06/30/2026 1082435000
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,845.12 08/19/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A randomized double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) in US Black/African American & Hispanic patient populations with elevated Lp(a) and established atherosclerotic cardiovascular disease No dispute reported 06/30/2026 1089692877
Principal investigator 1 Braintree Laboratories, Inc. $1,822.10 08/16/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201784
Principal investigator 1 Janssen Research & Development, LLC $670.00 08/14/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980671
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $98,816.15 08/09/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1081188322
Principal investigator 1 PFIZER INC. $42,004.10 08/06/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131030279
Principal investigator 1 Braintree Laboratories, Inc. $500.00 08/01/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120201452
Principal investigator 1 ModernaTX, Inc. $45,490.41 08/01/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191726
Principal investigator 1 Braintree Laboratories, Inc. $70.00 07/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201342
Principal investigator 1 Braintree Laboratories, Inc. $140.00 07/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201344
Principal investigator 1 Braintree Laboratories, Inc. $2,533.65 07/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201346
Principal investigator 1 Braintree Laboratories, Inc. $8,270.00 07/31/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201348
Principal investigator 1 PFIZER INC. $11,500.00 07/30/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131046258
Principal investigator 1 ModernaTX, Inc. $856.68 07/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191654
Principal investigator 1 ModernaTX, Inc. $29,285.83 07/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191656
Principal investigator 1 Janssen Research & Development, LLC $335.00 07/25/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980585
Principal investigator 1 ModernaTX, Inc. $9,231.30 07/24/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191596
Principal investigator 1 Braintree Laboratories, Inc. $3,188.20 07/19/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200952
Principal investigator 1 Braintree Laboratories, Inc. $5,531.61 07/17/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200804
Principal investigator 1 ModernaTX, Inc. $9,498.56 07/03/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147191592
Principal investigator 1 ModernaTX, Inc. $3,263.34 07/03/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191594
Principal investigator 1 Janssen Research & Development, LLC $670.00 06/28/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980499
Principal investigator 1 Braintree Laboratories, Inc. $700.00 06/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200698
Principal investigator 1 Braintree Laboratories, Inc. $700.00 06/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200710
Principal investigator 1 ModernaTX, Inc. $28,160.73 06/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191712
Principal investigator 1 ModernaTX, Inc. $14,991.90 06/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191722
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $22,785.00 06/20/2024 Non-covered Recipient Entity
Elligo Health Research Inc
LX9211.1-204-DPN No dispute reported 06/30/2026 1081187778
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,451.71 06/20/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089692683
Principal investigator 1 ModernaTX, Inc. $19,344.15 06/19/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191718
Principal investigator 1 Braintree Laboratories, Inc. $415.00 06/06/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200358
Principal investigator 1 Braintree Laboratories, Inc. $415.00 06/06/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120200404
Principal investigator 1 PFIZER INC. $2,862.48 06/05/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131068770
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $453.00 05/29/2024 Non-covered Recipient Entity
WIRB COPERNICUS GROUP INC
LX9211.1-204-DPN No dispute reported 06/30/2026 1081187728
Principal investigator 1 ModernaTX, Inc. $924.75 05/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191700
Principal investigator 1 ModernaTX, Inc. $25,272.06 05/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191708
Principal investigator 1 ModernaTX, Inc. $152,214.05 05/27/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191710
Principal investigator 1 PFIZER INC. $129,723.84 05/24/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131078809
Principal investigator 1 ModernaTX, Inc. $10,940.04 05/17/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191446
Principal investigator 1 ModernaTX, Inc. $841.00 05/08/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191698
Principal investigator 1 PFIZER INC. $41.25 05/01/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131078748
Principal investigator 1 ModernaTX, Inc. $4,910.08 04/26/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147191408
Recipient Lexicon Pharmaceuticals, Inc. $266.45 04/25/2024 Covered Recipient Physician LX9211 No dispute reported 06/30/2026 1081189938
Recipient Lexicon Pharmaceuticals, Inc. $1,105.47 04/25/2024 Covered Recipient Physician LX9211 No dispute reported 06/30/2026 1081189988
Recipient Lexicon Pharmaceuticals, Inc. $242.06 04/25/2024 Covered Recipient Physician LX9211 No dispute reported 06/30/2026 1081189990
Principal investigator 1 Amgen Inc. $45,715.00 04/20/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096308989
Principal investigator 1 Amgen Inc. $13,465.09 04/20/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315817
Principal investigator 1 Janssen Research & Development, LLC $670.00 04/19/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980661
Principal investigator 1 PFIZER INC. $9,112.50 04/17/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131091929
Principal investigator 1 ModernaTX, Inc. $10,020.40 04/10/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191424
Principal investigator 1 Janssen Research & Development, LLC $1,005.00 04/09/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980553
Principal investigator 1 PFIZER INC. $469.60 04/09/2024 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131023942
Principal investigator 1 ModernaTX, Inc. $207.00 04/05/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147191426
Principal investigator 1 PFIZER INC. $5,555.29 04/05/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131092528
Principal investigator 1 Braintree Laboratories, Inc. $2,523.94 04/04/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199552
Principal investigator 1 Braintree Laboratories, Inc. $2,523.94 04/04/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199630
Principal investigator 1 ModernaTX, Inc. $12,946.50 03/28/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191682
Principal investigator 1 PFIZER INC. $21,728.04 03/28/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131099958
Principal investigator 1 ModernaTX, Inc. $4,600.40 03/27/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147182997
Principal investigator 1 Braintree Laboratories, Inc. $108.00 03/21/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199454
Principal investigator 1 Braintree Laboratories, Inc. $108.00 03/21/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199474
Principal investigator 1 ModernaTX, Inc. $27,150.12 03/21/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191678
Principal investigator 1 ModernaTX, Inc. $1,713.36 03/21/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191688
Principal investigator 1 Biogen, Inc. $57,196.65 03/20/2024 Non-covered Recipient Entity
Elligo Health Research
A Phase 2 Study of RTA 901 in Patients With Diabetic Peripheral Neuropathic Pain (CYPRESS) (CYPRESS) No dispute reported 06/30/2026 1104839942
Principal investigator 1 ModernaTX, Inc. $10,530.84 03/20/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182993
Principal investigator 1 ModernaTX, Inc. $9,901.00 03/15/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147182995
Principal investigator 1 Braintree Laboratories, Inc. $1,961.38 03/14/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199192
Principal investigator 1 Braintree Laboratories, Inc. $1,961.38 03/14/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199308
Principal investigator 1 ModernaTX, Inc. $85.00 03/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191674
Principal investigator 1 Janssen Research & Development, LLC $800.00 03/08/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980517
Principal investigator 1 Janssen Research & Development, LLC $425.00 03/08/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980539
Principal investigator 1 Janssen Research & Development, LLC $1,320.00 03/08/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980621
Principal investigator 1 Janssen Research & Development, LLC $1,405.00 03/08/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980635
Principal investigator 1 Janssen Research & Development, LLC $6,844.00 03/08/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980703
Principal investigator 1 Janssen Research & Development, LLC $360.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980247
Principal investigator 1 Janssen Research & Development, LLC $120.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980309
Principal investigator 1 Janssen Research & Development, LLC $556.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980339
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980343
Principal investigator 1 Janssen Research & Development, LLC $100.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980353
Principal investigator 1 Janssen Research & Development, LLC $120.00 03/07/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980373
Principal investigator 1 Braintree Laboratories, Inc. $108.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199028
Principal investigator 1 Braintree Laboratories, Inc. $140.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199030
Principal investigator 1 Braintree Laboratories, Inc. $1,346.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199032
Principal investigator 1 Braintree Laboratories, Inc. $108.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199048
Principal investigator 1 Braintree Laboratories, Inc. $140.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199050
Principal investigator 1 Braintree Laboratories, Inc. $1,346.00 02/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120199052
Principal investigator 1 ModernaTX, Inc. $16,029.00 02/28/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes No dispute reported 06/30/2026 1147191672
Principal investigator 1 Janssen Research & Development, LLC $7,663.40 02/27/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980291
Principal investigator 1 PFIZER INC. $87,776.10 02/27/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131100005
Principal investigator 1 Amgen Inc. $336.94 02/26/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
SHUTTLE P3 AD Adult Combo TCS No dispute reported 06/30/2026 1096315819
Principal investigator 1 ModernaTX, Inc. $15,824.43 02/26/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191664
Principal investigator 1 ModernaTX, Inc. $41,548.98 02/26/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191670
Principal investigator 1 ModernaTX, Inc. $1,000.00 02/16/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191662
Principal investigator 1 ModernaTX, Inc. $4,700.44 02/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147182981
Principal investigator 1 ModernaTX, Inc. $10,942.02 02/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182987
Principal investigator 1 ModernaTX, Inc. $1,376.00 02/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182989
Principal investigator 1 ModernaTX, Inc. $288.00 02/14/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182991
Principal investigator 1 PFIZER INC. $10,256.00 02/14/2024 Non-covered Recipient Entity
Elligo Health Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131100000
Principal investigator 1 ModernaTX, Inc. $320.16 02/09/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182983
Principal investigator 1 ModernaTX, Inc. $72.00 02/09/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182985
Principal investigator 1 Merck Sharp & Dohme LLC $14,200.00 02/05/2024 Non-covered Recipient Entity
Acclaim Clinical Research
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine na ve Adults No dispute reported 06/30/2026 1136436547
Principal investigator 1 Braintree Laboratories, Inc. $139.00 02/02/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198546
Principal investigator 1 Braintree Laboratories, Inc. $139.00 02/02/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198656
Principal investigator 1 Novartis Pharmaceuticals Corporation $34,533.22 01/30/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients (VICTORION-1 PREVENT) No dispute reported 06/30/2026 1089696669
Principal investigator 1 ModernaTX, Inc. $50,424.14 01/29/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147191634
Principal investigator 1 Eli Lilly and Company $393.75 01/25/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137359357
Principal investigator 1 Janssen Research & Development, LLC $100.00 01/25/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980493
Principal investigator 1 Janssen Research & Development, LLC $2,160.00 01/25/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980503
Principal investigator 1 Janssen Research & Development, LLC $1,628.00 01/25/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980569
Principal investigator 1 ModernaTX, Inc. $3,424.14 01/24/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182975
Principal investigator 1 Amgen Inc. $8,526.14 01/19/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
ASCEND P3 AD Extension No dispute reported 06/30/2026 1096308991
Principal investigator 1 Janssen Research & Development, LLC $2,742.80 01/18/2024 Non-covered Recipient Entity
Elligo Hlth Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1078980633
Principal investigator 1 ModernaTX, Inc. $96,088.74 01/18/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147191642
Principal investigator 1 ModernaTX, Inc. $9,231.30 01/17/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147182979
Principal investigator 1 ModernaTX, Inc. $45,490.41 01/16/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147191638
Principal investigator 1 PFIZER INC. $352.20 01/16/2024 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131023948
Principal investigator 1 PFIZER INC. $26.32 01/16/2024 Non-covered Recipient Entity
Acclaim Clinical Research
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A COMBINED MODIFIED RNA VACCINE CANDIDATE AGAINST COVID19 AND INFLUENZA IN HEALTHY INDIVIDUALS No dispute reported 06/30/2026 1131024007
Principal investigator 1 AstraZeneca Pharmaceuticals LP $25,750.00 01/12/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH, INC
A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis No dispute reported 06/30/2026 1110844510
Principal investigator 1 PFIZER INC. $11,178.00 01/06/2024 Non-covered Recipient Entity
Elligo Health Research Inc
AN INTERVENTIONAL PHASE 23 ADAPTIVE MULTICENTER RANDOMIZED DOUBLEBLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS No dispute reported 06/30/2026 1131110030
Principal investigator 1 ModernaTX, Inc. $4,979.04 01/05/2024 Non-covered Recipient Entity
ACCLAIM CLINICAL RESEARCH
A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults No dispute reported 06/30/2026 1147182977
Principal investigator 1 Braintree Laboratories, Inc. $5,813.31 01/04/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198104
Principal investigator 1 Braintree Laboratories, Inc. $5,813.31 01/04/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Non-Erosive Reflux Disease No dispute reported 06/30/2026 1120198310
Principal investigator 1 Eli Lilly and Company $98,658.00 01/02/2024 Non-covered Recipient Entity
ELLIGO HEALTH RESEARCH INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1137358923